Clinical expansion Beyond Air is actively raising visibility through participation in high-profile investor conferences and events (Cantor Global Healthcare Conference, Roth Conference, H.C. Wainwright Global Investment Conference), presenting opportunities to engage with potential healthcare providers, distributors, and strategic partners seeking nitric oxide based therapies and pulmonary solutions.

Financing runway With recent financing of up to 32 million and a robust funding history, there is appetite for partnerships that can accelerate deployment of the LungFit PH system and expand commercialization in new markets, suggesting a need for channel partners, OEM relationships, and co-marketing arrangements.

Regulatory readiness As a commercial stage medical device and biopharmaceutical entity focused on nitric oxide therapy, Beyond Air likely seeks robust clinical data, regulatory clarity, and hospital adoption pathways—presenting opportunities for clinical partners, contract research organizations, and integrated supply chain collaborators.

Strategic partnerships Collaborations like the Hebrew University of Jerusalem program indicate interest in neurology and ASD applications, opening doors for cross-disciplinary partnerships, research collaborations, and international market expansion beyond respiratory indications.

Operational scale The company operates with a lean team (51-200 employees) yet pursues rapid deployment of its LungFit system, signaling a need for scalable sales channels, distributor networks, and customer success teams to drive adoption in hospitals, clinics, and government facilities.